Amylyx Pharmaceuticals, Inc.

    Jurisdiction
    United States
    ISIN
    US03237H1014 (AMLX)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    4 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    -€212.38K
    Gross margin
    545.8%
    EBIT
    -€168.01M
    EBIT margin
    79,106.4%
    Net income
    -€160.01M
    Net margin
    75,341.4%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €68.24K -132.1% -€131.57M -17.8%
    €33.43M +48,887.5% -€135.37M +2.9%
    €89.99M +169.2% -€92.02M -32.0%

    Dividends

    Last dividend amount
    $0.42
    Ex date
    Payment date

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Mazzariello Gina Chief Legal Officer -30K $8.20 -$246.00K

    Earnings Calls

    Latest earnings call: July 10, 2024

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 515K $1.82M +51K Buy

    Add to watchlist

    Notifications